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1  |  INTRODUCTION
The visual cortex has been an established model for plasticity 
studies for decades (Hubel & Wiesel, 1963). The visual cor-
tex matures during a critical period of increased sensitivity 
to environmental stimuli, during which developing neuronal 
networks are shaped based on experience. It was long thought 
that plasticity declines soon after the critical period ends and 
remains restricted throughout adulthood.
Previous studies have shown that the antidepressant fluox-
etine, when combined with monocular deprivation (MD), can 
restore developmental‐like plasticity in the visual cortex of rats 
and mice (Maya Vetencourt et al., 2008; Steinzeig, Molotkov, & 
Castrén, 2017). The plasticity‐promoting effect of antidepressants 
is not limited to the visual system, but extends to other brain areas 
as well, including regions responsible for processing fear and 
Controlling emotions (Karpova et al., 2011; Mikics et al., 2018).
Additional studies have demonstrated that antidepres-
sants promote neural plasticity on different levels: they en-
hance hippocampal neurogenesis (Malberg, Eisch, Nestler, 
& Duman, 2000; Santarelli, 2003) and increase signalling 
of brain‐derived neurotrophic factor (BDNF) through its 
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Abstract
Heightened neuronal plasticity expressed during early postnatal life has been thought 
to permanently decline once critical periods have ended. For example, monocular dep-
rivation is able to shift ocular dominance in the mouse visual cortex during the first 
months of life, but this effect is lost later in life. However, various treatments, such as 
the antidepressant fluoxetine, can reactivate a critical period‐like plasticity in the adult 
brain. When monocular deprivation is supplemented with chronic fluoxetine adminis-
tration, a major shift in ocular dominance is produced after the critical period has ended. 
In the current study, we characterized the temporal patterns of fluoxetine‐induced plas-
ticity in the adult mouse visual cortex, using in vivo optical imaging. We found that 
artificially induced plasticity in ocular dominance extended beyond the duration of the 
naturally occurring critical period and continued as long as fluoxetine was adminis-
tered. However, this fluoxetine‐induced plasticity period ended as soon as the drug 
was not given. These features of antidepressant‐induced plasticity may be useful when 
designing treatment strategies involving long‐term antidepressant treatment in humans.
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receptor TrkB (Björkholm & Monteggia, 2016; Duman 
& Monteggia, 2006; Nibuya, Morinobu, & Duman, 1995; 
Saarelainen et al., 2003), independently from serotonin trans-
porter (Rantamäki et  al., 2011). Hence, these data suggest 
that complex processes of neuronal plasticity and structural 
adaptation may underlie clinical effects of antidepressants.
In the current study, we used the visual cortex as a model 
to examine characteristics of fluoxetine‐induced plasticity in 
mice. While a naturally occurring critical period of plasticity 
lasts for roughly one month in the visual cortex of rodents, 
it has not been established whether fluoxetine‐induced plas-
ticity is confined to the same timeframe (Hensch, 2005). 
Here, we have studied whether a window of plasticity, in-
duced by fluoxetine, is dependent on treatment (i.e. remains 
open for the duration of the treatment, irrespective of time) 
or on time (i.e. intrinsically closes after a certain period, irre-
spective of treatment). To answer this question, we extended 
the standard fluoxetine treatment duration to three months 
and tested for visual plasticity of ocular dominance.
A novel class of rapid‐acting antidepressants has recently 
received considerable attention. While the conventional an-
tidepressant drugs (such as fluoxetine) require chronic treat-
ment for their action to begin (Wong & Licinio, 2001), a single 
dose of the N‐methyl‐d‐aspartate (NMDA) receptor antago-
nist, ketamine, demonstrates fast antidepressant effects that 
vastly outlast the presence of ketamine in the body (Zarate 
et  al., 2006). It is not clear whether the plasticity‐inducing 
actions of fluoxetine also outlast the presence of the drug in 
the body. To assess the potentially prolonged effects of fluox-
etine in mice, we separated the drug treatment and monocular 
deprivation (MD) by testing the effect of MD after fluoxetine 
and its metabolites had been cleared from the body.
The structural basis for the plasticity induced by antide-
pressants remains under investigation. Growing evidence sug-
gests an important role of inhibitory neurons (Hensch, 2005). 
In particular, perineuronal nets (PNNs)—structures of extra-
cellular matrix formed around parvalbumin (PV)‐contain-
ing cells at the end of the critical period—could be potential 
candidates. Previous findings demonstrated that a reduction 
in PNNs accompanied plasticity in the visual cortex (Lensjø, 
Lepperød, Dick, Hafting, & Fyhn, 2017; Pizzorusso, 2002), 
dentate gyrus (Kobayashi et al., 2010) and amygdala (Karpova 
et al., 2011). Therefore, we assessed whether reduced PNN ex-
pression can contribute to the plasticity effects of fluoxetine.
2 |  MATERIALS AND METHODS
2.1 | Animals
All experiments were performed on adult female C57BL/6J Rcc 
mice delivered from Envigo (Harlan Laboratories). Animals 
were housed in standard cages and conditions (temperature 
22°C, 12‐hr light/dark cycle), and were provided with food and 
water ad libitum. Since the previous experiments have shown a 
period of elevated plasticity in the mouse visual cortex, where 
longer MD can cause an OD shift up to postnatal day 110, all the 
animals used in the current study were at least 130 days old at the 
time of the second imaging session (Lehmann & Löwel, 2008).
2.2 | Ethical statement
All experiments were performed according to insti-
tutional guidelines and were approved by the County 
Administrative Board of Southern Finland (Licences number: 
ESAVI/7551/04.10.07/2013; ESAVI/10300/04.10.07/2016). 
All the efforts were made to minimize animals suffering and 
number of animals used in experiments.
2.3 | Fluoxetine treatment and 
experimental groups
Our standard protocol to restore developmental‐like plasticity 
in the adult mice included four weeks of fluoxetine treatment. 
Specifically, fluoxetine hydrochloride (Bosche Scientific) 
was dissolved 80 mg/L in the drinking water for the treat-
ment group (Steinzeig et al., 2017). For the plasticity window 
experiments, we extended our protocol to 12 weeks (“Long 
treatment” group), rationalizing that this period significantly 
exceeds the natural critical period. Treatments longer than 
this could potentially be toxic, as shown in rats (Inkielewicz‐
Stępniak, 2011). For the second group, “Postponed MD”, we 
used the standard protocol (four weeks of fluoxetine treat-
ment) but postponed the start of MD until one week after the 
fluoxetine treatment ended. Control groups for all the experi-
ments underwent the same procedures but received regular 
tap water instead of fluoxetine solution. Water consumption 
was monitored twice a week in both groups; no decline in 
drinking was observed in the treatment group (Figure S1).
2.4 | Monocular deprivation
To test for cortical plasticity, the mice were monocularly de-
prived for one week in all groups. The eye contralateral to 
the hemisphere to be imaged was sutured shut with the silk 
thread (Ethicon) three mattress sutures under anaesthesia (see 
below). During the deprivation period, animals were checked 
daily to exclude those with spontaneous eye reopening. In the 
Long treatment group, MD occurred during the last week of 
fluoxetine treatment; in the Postponed MD group, it occurred 
one week after the last fluoxetine treatment.
2.5 | Surgical preparation for 
optical imaging
To prepare for the optical imaging experiment, mice under-
went transparent skull surgery as described earlier (for detailed 
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protocol, see Steinzeig et  al., 2017). Briefly, animals were 
anaesthetized with a mixture of fentanyl (Hameln, Germany) 
0.05  mg/kg, midazolam (Hameln, Germany) 5  mg/kg and 
medetomidine (Orion Pharma) 0.5  mg/kg. Additionally, 
carprofen 5 mg/kg (ScanVet) was administrated subcutane-
ously for postsurgery analgesia. During the surgery, animals 
were fixed to a stereotaxic frame and kept on a heating pad 
at 37°C to prevent hypothermia. The eyes were protected 
with eye gel (Viscotears, Alcon). The scalp around the visual 
cortex was removed, and the skull surface was cleaned of 
periosteum, blood and debris. A layer of cyanoacrylate glue 
Loctite 401 (Henkel) was applied, followed by two layers of 
acryl (EUBECOS) mixed with methyl methacrylate liquid 
(Dentsply). Finally, a metal bar holder was attached to the 
surface of the skull and then covered with a mixture of cy-
anoacrylate glue and dental cement (Dentsply) to guarantee a 
secure positioning during the optical experiments.
2.6 | Optical imaging
We evaluated ocular dominance with an intrinsic signal op-
tical imaging—a haemodynamic‐based method for brain 
imaging based on the blood oxygenation level and optical 
properties of the brain tissue underlined neuronal activity.
We utilized continuous‐periodic stimulation with contin-
uous synchronized data acquisition for the processing of the 
intrinsic signals (Cang, Kalatsky, LöWel, & Stryker, 2005; 
Kalatsky & Stryker, 2003). Intrinsic signals were recorded 
with a Dalsa 1M30 CCD camera (Teledyne‐Dalsa) and tan-
dem macro objective (50  ×  135  mm, Nikon). The visual 
stimulus was represented by a drifting  thin horizontal bar 
(2° wide) moving upwards on a high refresh rate stimulus 
monitor at a temporal frequency of 1 cycle/8.3 s (0.125 Hz) 
and a spatial frequency of 1/80  deg.  The visual stimulus 
was designed to evoke the response solely in the binoc-
ular area of the primary visual cortex. Therefore, the bar 
was restricted only to the central part of the screen (−15° 
to +5°). For the imaging experiment, the animals were an-
aesthetized with 1.2% isoflurane in a mixture of oxygen:air 
and placed on a heating pad facing the stimulus monitor, 
25  cm in front of the test subject. A vertical midline was 
aligned to the animal's nose. The physiological state of the 
animals was monitored throughout the experiment with the 
monitor (Physio Suite, Kent Scientific). The head of the an-
imal was firmly fixed during the recordings, and the eyes 
remained in a stable position throughout the experiment. 
First, the vascular maps were collected under green light 
illumination (540 ± 20 nm). Then, the camera was focused 
at 600 μm below the cortical surface to record the intrinsic 
signals under red light (625 ± 10 nm). The frames were col-
lected for 5 min for each eye at a rate of 30 fps and stored as 
a 512 × 512 pixel image after spatial binning of the camera 
images. To collect the cortical response for left and right 
eye stimulation independently, we alternately closed one 
eye with a patch.
Since the method allows repetitive measurements, we im-
aged the same animals twice: before (IOS I) and after MD 
(IOSII).
2.7 | IOS data analysis
Cortical maps were computed out of the raw video files 
using an analysis software package for continuous record-
ing of optical intrinsic signals (VK Imaging). Briefly, to 
generate primary visual cortex activation maps upon ipsi-
lateral and contralateral stimulation, the software analyses 
fractional changes in reflectance from the cortical surface 
on the frequency of stimulation and removes slow haemody-
namic artefacts using Fourier transform. To calculate ocular 
dominance indexes (ODIs), the ipsilateral activity map was 
smoothened with a low‐pass filter, thresholded at 30% of the 
peak response to improve signal‐to‐noise ratio and used as 
a mask to select the binocularly responding region. Then, 
within the binocularly responding region, the calculations of 
the ODI were made for each responsive pixel based on the 
formula (C − I)/(C + I), where “C” refers to the magnitude 
response of the contralateral eye and “I” refers to that of the 
ipsilateral eye. For each animal, a final result was obtained 
by averaging several ODIs. Positive values represent con-
tralateral dominance, while negative values represent ipsilat-
eral dominance.
2.8 | Immunohistochemistry
Coronal sections of 40  μm were cut with a vibratome. 
Staining procedures were performed on free‐floating sec-
tions under constant agitation. The lectin Wisteria flori-
bunda agglutinin (WFA) was used to visualize PNNs, as it 
recognizes N‐acetylgalactosamine‐containing epitopes in 
the CS‐GAG chains. The sections were quickly rinsed in 
1× PBS and blocked with 5% normal donkey serum (NDS) 
and 0.3% Triton X‐100 (Sigma) in 1× PBS for 1 hr at room 
temperature. The sections were then incubated for 2 days at 
4°C with a primary antibody cocktail of biotin‐conjugated 
WFA 1:200 (Sigma‐Aldrich, L1516) and guinea pig anti‐
parvalbumin 1:1,000 (Synaptic System, 195 004), diluted in 
1× PBS with 1% NDS and 0.3% Triton X‐100. After four 
rounds of 10‐min washings in 1× PBS, the slices were incu-
bated for 2 hr at room temperature with a secondary antibody 
cocktail composed of Streptavidin Alexa fluorophore 555 
conjugate 1:1,000 (Life Technologies, 1600216) and don-
key anti‐guinea pig Alexa fluorophore 488 1:200 (Jackson 
ImmunoResearch Europe Ltd., 706‐545‐148), in 1% NDS 
and 0.3% Triton X‐100 (Sigma) in 1× PBS. Finally, the 
slices were washed in 1× PBS four times for 10 min each 
time, mounted in PB 0.1 M on Super frost slides and cover 
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slipped using fluorescence mounting medium (Dako North 
America).
2.9 | Confocal microscopy and PV‐
PNN counting
All slides were coded during the quantitative evaluation of 
immunostainings to perform the analysis blindly. The pri-
mary visual cortex was analysed (areas identical to adult 
bregma from −2.80 to −3.52) and was determined according 
to the mouse brain atlas (Paxinos & Franklin, 2nd edition). 
From each brain, two to three sections were selected and 
Z‐stack images of 2 μm steps were obtained with a confo-
cal microscope LSM 700 (Carl Zeiss) equipped with a 10× 
objective lens (10× Plan‐Apochromat 10×/0.45, Carl Zeiss) 
and imaging Software ZEN 2012 lite (Zeiss). The same 
microscope and camera settings were used for all of the 
slides. Image processing was done using ImageJ Software 
(National Institutes of Health). The region of interest (ROI) 
was selected in the primary visual cortex and then subdi-
vided into six layers, using the ROI manager of ImageJ soft-
ware. The minimum filter function of ImageJ with a radius 
of 0.5 pixel was used for all of the pictures from the Control, 
Long treatment and Postponed MD groups, in order to de-
crease the potential influence of random and punctate 
auto‐fluorescence on the counting procedure. This did not 
result in a loss of information. This filter uses a greyscale 
erosion; in particular, by setting the radius at 0.5 pixel, the 
filter replaces the pixel with the minimum pixel value of 
the four immediate neighbours. The number of parvalbu-
min‐positive (PV+), PNN‐positive (PNN+) and co‐localized 
PV+PNN+ cells was manually counted in each image using 
the Cell Counter tool of ImageJ. Cells were considered posi-
tive and counted if they displayed a PV staining throughout 
the soma for the PV+, and a clear ring around the soma for 
the PNN+, and all the neurons fulfilling these criteria were 
counted as positive regardless of their size or intensity of 
staining. All cells entirely within the boundaries of the area 
were counted; those in contact with the top border of each 
layer were considered in that layer, and those that were in 
contact with the lower border of the layer were excluded 
from that layer count.
2.10 | PV intensity measurements
To assess the intensity of parvalbumin‐positive interneu-
rons in layers 2–3 and 4 of the visual cortex, maximum 
intensity pictures were obtained from the original z‐stack 
pictures. The profiles of the PV cells were selected with 
the selection tool of ImageJ and a circular ROI where there 
was no signal was taken as background for each layer. Area 
mean grey value and integrated density were measured 
for each selected ROI. To calculate the intensity of flu-
orescence or CTCF (corrected total cell fluorescence), a 
formula defined in the ImageJ‐win64 manual was used: 
CTCF = Integrated density − (Area selected cell × Mean 
fluorescence of background reading). Then, the averaged 
CTCF for each layer and picture was calculated and nor-
malized for the number of cells in that layer.
2.11 | Statistical analysis
In optical imaging experiments, groups were compared using 
analysis of variance (ANOVA) and Student's t tests. For post 
hoc analysis, we performed Sidak's test for multiple com-
parisons. Data from immunohistochemistry analysis were 
compared with the non‐parametric Mann–Whitney test, fol-
lowed by the Dunn's multiple comparison test as post hoc 
in case of significance. For PV intensity, non‐parametric 
Kruskal–Wallis test was used. Significance levels were set 
as *p < .05; **p < .01; and ***p < .001. Data are presented 
as means ± SEM, with n indicating the number of animals. 
Statistical analysis was conducted with GraphPad Prism soft-
ware version 6.00 (GraphPad).
3 |  RESULTS
3.1 | The window of induced plasticity 
stays open as long as the fluoxetine treatment 
continues
To determine whether the window of fluoxetine‐induced plas-
ticity remains open as long as the treatment continues, we ex-
tended peroral fluoxetine treatment from the basic protocol of 
4–12 weeks (Figure 1). Specifically, to test the OD plasticity, 
we used optical imaging of intrinsic signals (IOS) to assess ocu-
lar dominance in the visual cortex after 7 days of MD. The IOS 
data demonstrated that after 12 weeks of fluoxetine (80 mg/L in 
the drinking water), closing the eye for 7 days resulted in a shift 
in OD from 0.2 ± 0.03 to −0.01 ± 0.03 (one‐way ANOVA, 
Sidak‐corrected). This was indicative of an ipsilateral (open) 
eye dominance. In the Control group, ODIs remained stable 
(before MD 0.19  ±  0.02; after MD 0.19  ±  0.02; Figure  2). 
Analysis of the cortical activation measured by average mag-
nitude of the signal showed significant decrease in the closed 
eye response in fluoxetine group (Control: 5.1 ± 0.43; fluox-
etine: 3.8 ± 0.2 n = 8) and non‐significant open eye increase 
(Control: 4.2 ± 0.30; fluoxetine: 4.6 ± 0.17; n = 8; ANOVA, 
Sidak‐corrected; Figure 3). Therefore, after 12 weeks of con-
tinuous fluoxetine treatment, MD retains robust effects on bin-
ocularity, indicating that continuous fluoxetine treatment keeps 
the window of critical period‐like plasticity open for at least 
three months—much longer than the naturally occurring criti-
cal period.
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3.2 | Fluoxetine promotes changes in OD 
plasticity only during the treatment
To determine whether fluoxetine treatment could evoke long‐
lasting changes in brain plasticity after the drug is cleared 
from the body, we first measured serum concentration of 
fluoxetine and its active metabolite norfluoxetine after a 4‐
week treatment. We found that serum levels of fluoxetine 
declined quickly within 72 hr and were below detection limit 
after 7 days following drug withdrawal (Table S1). At 24 hr, 
the serum concentration of norfluoxetine was 10‐fold higher 
than that of fluoxetine, but at 7 days, only trace levels were 
detectable. Thus, for this set of experiments, we Postponed 
the MD to begin 7 days after the last fluoxetine treatment 
(Figure  1). OD plasticity in the primary visual cortex was 
tested after 7 days of MD (Postponed MD, Figure 1). The 
average ODIs for the Postponed MD group were not statis-
tically different from that of the Control group: ODIs be-
fore MD 0.19 ± 0.02; after MD 0.21 ± 0.03 (paired t test; 
Figure  4). Thus, the OD plasticity window in response to 
MD is only open when fluoxetine is in the body; after fluox-
etine and norfluoxetine were eliminated from the serum, the 
plasticity window is closed.
3.3 | Fluoxetine‐induced OD shift was not 
accompanied by a reduction in parvalbumin or 
perineuronal nets
To examine whether a change in PNNs around PV cells 
might serve as a source for enhanced plasticity, we in-
vestigated PNNs with confocal microscopy. We counted 
the PNN+ (WFA positive), parvalbumin‐positive (PV+) 
cells and co‐localization of these two signals (PV+PNN+) 
in brain slices (Figure  5a). As an additional parameter, 
we also calculated the ratio of PV+PNN+ neurons to PV+ 
cells (i.e. the percentage of PV+ cells surrounded with 
PNN out of all PV+ cells; Balmer, Carels, Frisch, & Nick, 
2009). The immunostaining demonstrated no significant 
difference either in the total amount of PNN+s, PV+s, 
nor in PV+PNN+s: (PNN+: Control = 43 ± 3, Long treat-
ment = 44 ± 2, Postponed MD = 36 ± 4; p > .05; PV+: 
Control = 98 ± 6, Long treatment = 91 ± 4, Postponed 
MD  =  73  ±  8; p  >  .05; PV+PNN+: Control  =  36  ±  2, 
Long treatment  =  37  ±  2, Postposed MD  =  30  ±  5; 
p  >  .05, n  =  4 animals per group, Kruskal–Wallis test; 
Figure  5b). Furthermore, no changes in PV+PNN+/PV+ 
ratio were observed (Control  =  41  ±  3%; Long treat-
ment  =  40  ±  2%; Postponed MD  =  40  ±  2%; n  =  4 
animals per group, Kruskal–Wallis test; Figure 5c). In ad-
dition, when these parameters were analysed separately 
for each layer, we only observed a significant reduction 
in PV+ cell number in the fourth cortical layer in the 
Postponed MD group; the PV+PNN+/PV ratio remained 
stable (Figure 5d–g). Consequently, there was no corre-
lation between fluoxetine‐induced plasticity and number 
of PV+, PNN+, or PV+PNN+ double positive cells, or in 
their ratio. Additionally, we have analysed intensity of 
the PV cells, since different PV content was shown to 
indicate the plasticity level in the hippocampus (Donato, 
Rompani, & Caroni, 2013). However, our brain sam-
ples demonstrated no significant changes in PV intensity 
(Figure S2).
F I G U R E  1  Experimental design. (a) Standard protocol for fluoxetine‐induced plasticity, four‐week treatment with fluoxetine 80 mg/kg 
dissolved in the drinking water, combined with monocular deprivation during the last week. (b) “Postponed monocular deprivation” protocol, after 
4 weeks of fluoxetine treatment, one‐week period of the drug wash‐out was added before the eye closure. (c) “Long treatment” protocol, fluoxetine 
treatment was expanded to 12 weeks and monocular deprivation applied during the last week. For each group, first imaging session took place 
before monocular deprivation and the second one just after the eye reopening
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4 |  DISCUSSION
The present study shows that the antidepressant fluoxetine 
restores plasticity in the adult mouse brain, and the window 
of this plasticity remains open as long as the treatment con-
tinues. Interestingly, the window of induced plasticity ex-
ceeded the natural critical period of plasticity in the rodent 
visual cortex. These data are consistent with previous find-
ings on the plasticity‐enhancing effects of enriched environ-
ments on ocular dominance (Greifzu, Kalogeraki, & Löwel, 
2016; Greifzu et al., 2014). Thus, these findings confirm the 
view that cortical plasticity is not restricted to early develop-
ment but can be reactivated and maintained in adulthood.
Previous studies using visually evoked potentials have 
shown that MD during fluoxetine treatment in adult rodents 
leads to a reduction in the responses to the closed eye without 
any significant strengthening of open eye responses, which 
is typically observed with MD responses during the critical 
period (Maya Vetencourt, Tiraboschi, Spolidoro, Castrén, & 
Maffei, 2011; Maya Vetencourt et  al., 2008). Furthermore, 
fluoxetine has no effects on vision in the absence of MD, 
as assessed with either evoked potentials or imaging of in-
trinsic signals (Maya Vetencourt et al., 2008; Steinzeig et al., 
2017), and actually improves vision in an amblyopic eye in 
adulthood, when the better eye is patched during fluoxetine 
treatment (Maya Vetencourt et al., 2008). In agreement with 
F I G U R E  2  Monocular deprivation 
leads to a robust shift in ocular dominance 
after long‐term treatment with fluoxetine 
(12 weeks). (a) Ocular dominance indexes 
of fluoxetine‐treated (IOSI 0.2 ± 0.03, IOSII 
−0.01 ± 0.03; n = 8) and Control groups 
(IOSI 0.19 ± 0.02, IOSII 0.19 ± 0.02; 
n = 5; one‐way ANOVA, Sidak‐corrected). 
(b–d) Representative optical imaging 
data: optical maps of cortical activity in 
the binocular part of the primary visual 
cortex, evoked by a drifting bar stimulus. 
The Control animals’ ipsilateral patch of 
activity is smaller, whereas in fluoxetine‐
treated animals almost indistinguishable 
from contralateral patch. That shows the 
reduction in the response of the closed eye 
after monocular deprivation and corresponds 
to lower OD indexes in these animals. b: 
Control group; c and d: fluoxetine‐treated. 
Colour maps reflect relative retinotopy; 
black and white—magnitude of the optical 
signal. The grey scale below the magnitude 
maps: fractional change in reflection ×104. 
The grey circle shows brain axes. Scale 
bar = 1 mm. [Colour figure can be viewed 
at wileyonlinelibrary.com]
F I G U R E  3  Primary visual cortex activation caused by 
stimulation of the contralateral and ipsilateral eye after MD. In 
fluoxetine‐treated group, OD shift was mediated by a significant 
decrease of deprived contralateral eye response (Control: 5.1 ± 0.43; 
fluoxetine: 3.8 ± 0.2; n = 8), and only insignificant increase in the 
open ipsilateral eye (Control: 4.2 ± 0.30; fluoxetine: 4.6 ± 0.17; n = 8; 
ANOVA, Sidak‐corrected)
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the previous data on the character of the fluoxetine‐induced 
plasticity, analysis of the visual cortical activity revealed de-
crease in the deprived eye response and a slight increase in 
the non‐deprived eye—a pattern typical for juvenile‐like OD 
plasticity.
We also tested whether fluoxetine affects visual cortex 
plasticity only while present in the body. We found that once 
the drug and its active metabolite have been cleared, mon-
ocular deprivation did not produce any shift in ocular domi-
nance. While this finding is expected from a pharmacological 
perspective, the antidepressant effects of ketamine have been 
found to vastly outlast its presence in the body; therefore, we 
tested whether fluoxetine induces similar lasting effects on 
OD plasticity. It is, however, possible that even longer dura-
tion of the fluoxetine treatment before the drug withdrawal 
might produce longer‐lasting effects on plasticity.
Although it has been considered that once reduced at the 
end of critical periods, plasticity remains restricted the rest of 
the lifetime, and it has recently been shown that a number of 
different treatments can reactivate critical period‐like plas-
ticity in the adult brain, including environmental enrichment, 
disruption of PNNs, genetic manipulations as well as several 
drug treatments, such as fluoxetine, valproate and inhibitors 
of acetylcholinesterase (Bavelier, Levi, Li, Dan, & Hensch, 
2010; Morishita & Hensch, 2008; Sale, Berardi, & Maffei, 
2014; Umemori, Winkel, Didio, Llach Pou, & Castrén, 2018). 
However, it is not clear whether the different treatments that 
induce adult plasticity are sharing a common mechanistic 
pathway or whether there are several parallel mechanisms 
that independently can lead to a similar induction of critical 
period‐like plasticity in the adult brain.
The exact mechanisms through which fluoxetine acts to 
reactivate plasticity remain also unclear. It has been shown 
that the activation of serotonin 1A receptors and BDNF sig-
nalling through TrkB receptor is required (Maya Vetencourt 
et  al., 2008, 2011), but how these signalling pathways are 
related to each other and through what cell types these ef-
fects are mediated are not known. Ongoing studies in our 
laboratory are addressing these questions through transcrip-
tomic and proteomic analyses as well as electrophysiological 
recordings, and we expect to be able to shine light on these 
mechanisms in the near future.
Maturation of PV+‐ interneurons and PNN formation 
takes place towards the end of the naturally occurring criti-
cal period in the visual cortex (Huang et al., 1999), and PV 
and PNN densities are well‐established markers of the criti-
cal period closure (Pizzorusso, 2002). Enzymatic removal of 
PNN by chondroitinase ABC injection is reopens the critical 
F I G U R E  4  Effects of fluoxetine on 
plasticity are absent when the monocular 
deprivation was postponed for one week 
after the end of the treatment. (a) Ocular 
dominance indexes before (0.19 ± 0.02) and 
after (0.21 ± 0.03) monocular deprivation 
(paired t test, n = 5); (b–d) representative 
optical imaging data: optical maps of 
cortical activity in the binocular part of 
the primary visual cortex, evoked by a 
drifting bar stimulus. b: Control group; 
c and d: fluoxetine‐treated. Colour maps 
reflect relative retinotopy; black and 
white—magnitude of the optical signal. 
The grey scale below the magnitude maps: 
fractional change in reflection ×104. 
The grey circle shows brain axes. Scale 
bar = 1 mm. [Colour figure can be viewed 
at wileyonlinelibrary.com]
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period in adult rodents in the same way as fluoxetine does 
(Lensjø et al., 2017; Pizzorusso, 2002). Several studies have 
demonstrated that chronic fluoxetine treatment in adult mice 
leads to a reduction in PNN+, PV+ or PV+ cells surrounded 
with PNN in different brain areas, such as the basolateral 
amygdala, medial frontal cortex and hippocampus (Karpova 
et al., 2011; Ohira, Takeuchi, Iwanaga, & Miyakawa, 2013). 
It has therefore been suggested that fluoxetine‐induced 
OD plasticity could, at least in part, involve the reduction 
in PNNs surrounding PV+ interneuron cells. However, the 
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effect of fluoxetine on PNNs appears to be dependent on 
the treatment protocol and is moderate in size (Ohira et al., 
2013). Despite these previous indications that PV and PNN 
density might be related to visual plasticity during the critical 
period as well as to plasticity in other brain regions during 
adulthood, we did not observe such changes in any of these 
parameters tested after 12 weeks of fluoxetine treatment. As 
our treatment lasted longer than that in the previous stud-
ies, it is possible that compensatory mechanisms take place 
during the long treatment, thereby restoring PNNs back to 
normal levels. Of note, PNN changes can sometimes only 
be appreciated in terms of their intensity; however, the in-
tensity measurements were unfortunately not unavailable for 
this study. Nevertheless, our findings suggest that changes in 
PV or PNN density are not necessary for fluoxetine‐induced 
plasticity in the adult visual cortex.
In the Postponed MD group, a small decline of PV+ cells 
was observed in the layer four of the primary visual cortex. 
A reduced number of PV+ neurons might reflect either a re-
duction in PV‐containing cells or a decrease in parvalbumin 
expression below detectable levels. The latter could be a sign 
of reduced inhibition by interneurons, although we did not 
see any accompanying changes in OD plasticity. Based on a 
concept proposed by Donato and colleagues, PV‐cell network 
in the hippocampus can be presented by two states: low or 
high PV. When low PV state possibly reflects elevated plas-
ticity, high PV is associated with memory consolidation. We 
thus tested PV cells intensity in the current study, however, 
found no detectable difference between the groups (Donato 
et al., 2013).
Our results emphasize the importance of combining flu-
oxetine with MD for promoting plasticity, since neither treat-
ment alone brings about an OD shift. Clinically, it is known 
that a combination of antidepressant treatment together with 
psychotherapy works better than pharmacotherapy alone 
(Pampallona, Bollini, Tibaldi, Kupelnick, & Munizza, 2004; 
Vittengl, Clark, Dunn, & Jarrett, 2007), which might reflect 
psychoterapy‐induced alterations in mood‐relevant circu-
tis rendered plastic by fluoxetine treatment (Castrén, 2005, 
2013; Castrén & Antila, 2017). However, treatment of de-
pression is typically initiated by antidepressant treatment 
alone and psychotherapy is added later. It was therefore im-
portant to investigate whether enhanced plasticity induced 
by fluoxetine spontaneously closes or whether it stays open 
as long as the treatment lasts. Our data now suggest that a 
spontaneous closure of plasticity period does not take place, 
which is consistent with finding using enriched environment 
(Greifzu et al., 2014, 2016). Therefore, if enhanced plasticity 
within mood‐related circuits took place during fluoxetine 
treatment in humans, environmental guidance such as psy-
chotherapy should be beneficial also after an extended treat-
ment with antidepressants alone.
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F I G U R E  5  Number of parvalbumin‐positive cells (PV+) or surrounding them perineuronal nets (PNN+) in the primary visual cortex was 
unaffected after 12‐week chronic fluoxetine treatment. (a) Representative confocal images. Parvalbumin (green) and WFA (red) immunoreactivity. 
The layers borders are drawn in yellow. Scale bar = 100 μm. (b) Counting results in the primary visual cortex. (PNN+: Control = 43 ± 3, Long 
treatment = 44 ± 2, Postponed MD = 36 ± 4—p > .05; PV+: Control = 98 ± 6, Long treatment = 91 ± 4, Postponed MD = 73 ± 8—p > .05; 
PV+PNN+: Control = 36 ± 2, Long treatment = 37 ± 2, Postposed MD = 30 ± 5—p > .05, n = 4 animals per group, Kruskal–Wallis test) 
(c). Percentage of PV cells surrounded with PNN in the primary visual cortex (Control = 41 ± 3%; Long treatment = 40 ± 2%; Postponed 
MD = 40 ± 2%—p > .05, n = 4 animals per group, Kruskal–Wallis test). (d) In the layers 6–5 of the primary visual cortex, no change was detected 
(PNN: Control = 17 ± 1; Long treatment = 19 ± 1; Postponed MD = 17 ± 2; p > .05; PV: Control = 40 ± 2; Long treatment = 41 ± 2, Postponed 
MD = 38 ± 4; p > .05; PNN‐PV: Control = 15 ± 1; Long treatment = 17 ± 2; Postponed MD = 14 ± 2; p > .05; n = 4 animals per group, Kruskal–
Wallis test). (e) In the fourth layer of the primary visual cortex, no change in the amount of perineuronal nets surrounding parvalbumin‐positive 
interneurons was detected; however, a significant reduction in PV+ cell number was observed in the Postponed MD group (PNN: Control = 17 ± 3; 
Long treatment = 16; Postponed MD = 11 ± 1; p > .05; PV: Control = 30; Long treatment = 28 ± 3; Postponed MD = 20 ± 2; Control versus Long 
treatment p > .05; Control versus Postponed MD *p = .028; PNN‐PV: Control = 15 ± 3; Long treatment = 12 ± 1; Postponed MD = 9 ± 1; p > .05; 
Kruskal–Wallis test and Dunn's test for multiple comparisons). (f) In the layers 3–2 of the primary visual cortex, no change was observed (PNN: 
Control = 9 ± 2; Long treatment = 10 ± 1; Postponed MD = 8 ± 1; p > .05; PV: Control = 18 ± 3; Long treatment = 1 ± 1; Postponed MD = 15 ± 2; 
p > .05; PNN‐PV: Control = 6 ± 1; Long treatment = 7 ± 1; Postponed MD = 6 ± 1; p > .05; n = 4 animals per group, Kruskal–Wallis test). (g) 
Percentage of PV cells surrounded with PNN in the different layers of the primary visual cortex (Layers 6–5: Control = 38 ± 3; Long treatment 43 ± 5; 
Postponed MD = 36 ± 1; p > .05. Layer 4: Control = 48 ± 1; Long treatment = 43 ± 2; Postponed MD 45 ± 3; p > .05. Layers 3/2: Control = 36 ± 4; 
Long treatment = 36 ± 4; Postponed MD = 38 ± 5; p > .05. Kruskal–Wallis test). [Colour figure can be viewed at wileyonlinelibrary.com]
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